Tumor necrosis factor- (cid:1) plays an important role in restenosis development

Genetic factors appear to be important in the restenotic process after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. TNF (cid:1)

[1]  L. Havekes,et al.  Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. , 2005, Cardiovascular research.

[2]  A. Zwinderman,et al.  Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. , 2004, European heart journal.

[3]  J. Franklyn,et al.  A systematic approach to the assessment of known TNF-alpha polymorphisms in Graves' disease. , 2004, Genes and immunity.

[4]  J. Haines,et al.  Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis , 2004, Annals of neurology.

[5]  Seung‐Jung Park,et al.  Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[6]  P. Serruys,et al.  Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction: A Clinical and Angiographic Study , 2003, Circulation.

[7]  A. Kastrati,et al.  Gender and restenosis after coronary artery stenting. , 2003, European heart journal.

[8]  A. Zwinderman,et al.  Estimation of Multilocus Haplotype Effects Using Weighted Penalised Log‐Likelihood: Analysis of Five Sequence Variations at the Cholesteryl Ester Transfer Protein Gene Locus , 2003, Annals of human genetics.

[9]  F. Welt,et al.  Inflammation and Restenosis in the Stent Era , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[10]  U. Ikeda,et al.  Chemokine expression in coronary circulation after coronary angioplasty as a prognostic factor for restenosis. , 2001, Atherosclerosis.

[11]  F. O'Gara,et al.  Tumour necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families , 2001, Genes and Immunity.

[12]  P. Quax,et al.  Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. , 2000, Circulation research.

[13]  M J Malloy,et al.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk. , 1999, Genome research.

[14]  K. Livak,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay. , 1999, Genetic analysis : biomolecular engineering.

[15]  KurtUlm,et al.  Bimodal Distribution of Angiographic Measures of Restenosis Six Months After Coronary Stent Placement , 1997 .

[16]  A. Kastrati,et al.  Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. , 1997, Circulation.

[17]  J. Zweier,et al.  Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. , 1997, Journal of the American College of Cardiology.

[18]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Polman,et al.  TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients , 1997, Journal of Neuroimmunology.

[20]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[21]  R. Frants,et al.  Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. , 1993, The Journal of biological chemistry.

[22]  D Schwartz,et al.  A Cascade Model for Restenosis: A Special Case of Atherosclerosis Progression , 1992, Circulation.

[23]  J. Jukema,et al.  Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. , 2005, Biomaterials.

[24]  W Li,et al.  Marker Selection by Akaike Information Criterion and Bayesian Information Criterion , 2001, Genetic epidemiology.

[25]  P. Galle,et al.  Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. , 2000, The Journal of investigative dermatology.

[26]  A. Hamsten,et al.  A common functional polymorphism (C-->A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. , 1999, Human molecular genetics.

[27]  D. Mark,et al.  Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. , 1994, Nucleic acids research.